Literature DB >> 25771986

In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.

Zhenying Guo1, Heather Hardin, Celina Montemayor-Garcia, Sofia Asioli, Alberto Righi, Francesca Maletta, Anna Sapino, Ricardo V Lloyd.   

Abstract

Some thyroid nodules such as follicular adenomas (FAs), follicular variant of papillary thyroid carcinomas (FVPTCs), and follicular thyroid carcinomas (FTCs) exhibit similar clinical presentations and gross morphologic appearances. The differential diagnosis of these lesions is sometimes difficult based on morphologic, cytologic, or clinical features alone. miR-146b-5p and miR-21 deregulation has been associated with progression and metastasis of thyroid cancers. However, the utility of in situ hybridization (ISH) to determine the cellular localization, diagnostic, and prognostic significance of miR-146b-5p and miR-21 expression in thyroid tumors has not been extensively analyzed. In order to examine the expression of miR-146b-5p and miR-21 in benign and malignant thyroid tissues and to determine if these microRNAs could be assigned to distinct histomorphological types of thyroid nodules, we analyzed miR-146b-5p and miR-21 expression in thyroid nodules on tissue microarrays (TMAs) with 193 thyroid specimens by ISH. miR-146b-5p and miR-21 expression in thyroid tissues was also analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). miR-146b-5p was highly expressed (89%) in papillary thyroid carcinomas (PTCs) and 41% of FVPTC. The expression of miR-146b-5p was not expressed in most FTCs, anaplastic thyroid carcinomas (ATCs), poorly differentiated thyroid carcinomas (PDTCs), or FAs (7, 8, 0, and 0%, respectively). MiR-21 was overexpressed in 83% of ATCs, 79 % of PTCs, 34% of FVPTCs, and 19% of PDTCs. The expression of miR-21 was not expressed in most FAs (9%) or FTCs (4%). Normal thyroid tissues and most benign goiters were negative for miR-146b-5p and miR-21. qRT-PCR analysis supported the ISH findings. PTC cases with positive expression of miR-146b-5p and miR-21 had significantly poorer disease-free survival rates. Immunohistochemical staining for HBME-1 showed positive staining in PTCs (100 %) and FVPTCs (92 %) with a subset of FTC (40%) staining positive, while all FAs were negative. Since miR-146b-5p was mainly expressed in PTC including FVPTC and was not expressed in most FTC, PDTC, or ATC, it may serve as a useful diagnostic marker for PTC. ISH is a useful method to analyze microRNA expression in formalin-fixed paraffin-embedded thyroid tissues.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25771986     DOI: 10.1007/s12022-015-9363-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  32 in total

1.  MicroRNA expression in zebrafish embryonic development.

Authors:  Erno Wienholds; Wigard P Kloosterman; Eric Miska; Ezequiel Alvarez-Saavedra; Eugene Berezikov; Ewart de Bruijn; H Robert Horvitz; Sakari Kauppinen; Ronald H A Plasterk
Journal:  Science       Date:  2005-05-26       Impact factor: 47.728

2.  MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4.

Authors:  Jing Zhang; Yang Yang; Yang Liu; Yuxia Fan; Zheng Liu; Xiaoming Wang; Qingling Yuan; Yixing Yin; Jie Yu; Meiju Zhu; Jian Zheng; Xiubo Lu
Journal:  J Surg Res       Date:  2014-02-15       Impact factor: 2.192

3.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Peng Yan Wu; Xu Dong Zhang; Jiang Zhu; Xiang Yun Guo; Jin Fen Wang
Journal:  Hum Pathol       Date:  2014-04-18       Impact factor: 3.466

5.  Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.

Authors:  Darya Buehler; Heather Hardin; Weihua Shan; Celina Montemayor-Garcia; Patrick S Rush; Sofia Asioli; Herbert Chen; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

6.  Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Authors:  Nobuki Nakamura; Lori A Erickson; Long Jin; Sabine Kajita; Heyu Zhang; Xiang Qian; Kandelaria Rumilla; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

7.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

8.  Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.

Authors:  Chen-Kai Chou; Kuender D Yang; Fong-Fu Chou; Chao-Cheng Huang; Yueh-Wen Lan; Ya-Fang Lee; Hong-Yo Kang; Rue-Tsuan Liu
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

9.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.

Authors:  Lorenzo F Sempere; Mette Christensen; Asli Silahtaroglu; Mads Bak; Catherine V Heath; Gary Schwartz; Wendy Wells; Sakari Kauppinen; Charles N Cole
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

10.  Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells.

Authors:  Santosh Kumar Patnaik; Eric Kannisto; Reema Mallick; Sai Yendamuri
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

View more
  20 in total

1.  In situ Detection of MicroRNAs: The Art of MicroRNA Research in Human Diseases.

Authors:  Duo Zhang; Lixin Xie; Yang Jin
Journal:  J Cytol Histol       Date:  2015-05-23

2.  Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.

Authors:  Yanping Wang; Heather Hardin; Ying-Hsia Chu; Karla Esbona; Ranran Zhang; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

3.  Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.

Authors:  Adam Covach; Sanjay Patel; Heather Hardin; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

4.  miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas.

Authors:  Nicla Borrelli; Maria Denaro; Clara Ugolini; Anello Marcello Poma; Mario Miccoli; Paolo Vitti; Paolo Miccoli; Fulvio Basolo
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

5.  Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms.

Authors:  Rakesh Mandal; Heather Hardin; Rebecca Baus; William Rehrauer; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

6.  MicroRNA-155 modulates bile duct inflammation by targeting the suppressor of cytokine signaling 1 in biliary atresia.

Authors:  Rui Zhao; Rui Dong; Yifan Yang; Yuqing Wang; Jin Ma; Jiang Wang; Hao Li; Shan Zheng
Journal:  Pediatr Res       Date:  2017-09-06       Impact factor: 3.756

7.  MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR.

Authors:  Ranran Zhang; Heather Hardin; Wei Huang; Jidong Chen; Sofia Asioli; Alberto Righi; Francesca Maletta; Anna Sapino; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 8.  Non-Coding RNAs in Thyroid Cancer.

Authors:  Ranran Zhang; Heather Hardin; Jidong Chen; Zhenying Guo; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 9.  MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.

Authors:  Chen-Kai Chou; Rue-Tusan Liu; Hong-Yo Kang
Journal:  Int J Mol Sci       Date:  2017-03-15       Impact factor: 5.923

10.  Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.

Authors:  Duško Dunđerović; Jasmina Marković Lipkovski; Ivan Boričic; Ivan Soldatović; Vesna Božic; Dubravka Cvejić; Svetislav Tatić
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.